Antidiuretic Hormone Receptor Antagonists
"Antidiuretic Hormone Receptor Antagonists" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Endogenous compounds and drugs that inhibit or block the activity of ANTIDUIRETIC HORMONE RECEPTORS.
| Descriptor ID |
D065092
|
| MeSH Number(s) |
D27.505.519.174 D27.505.696.560.311
|
| Concept/Terms |
Antidiuretic Hormone Receptor Antagonists- Antidiuretic Hormone Receptor Antagonists
- Vasopressin Antagonists
- Antagonists, Vasopressin
- Vasopressin Receptor Antagonists
- Antagonists, Vasopressin Receptor
- Receptor Antagonists, Vasopressin
- Antidiuretic Hormone Antagonists
- Antagonists, Antidiuretic Hormone
- Hormone Antagonists, Antidiuretic
|
Below are MeSH descriptors whose meaning is more general than "Antidiuretic Hormone Receptor Antagonists".
Below are MeSH descriptors whose meaning is more specific than "Antidiuretic Hormone Receptor Antagonists".
This graph shows the total number of publications written about "Antidiuretic Hormone Receptor Antagonists" by people in this website by year, and whether "Antidiuretic Hormone Receptor Antagonists" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2002 | 0 | 1 | 1 |
| 2008 | 0 | 1 | 1 |
| 2011 | 1 | 0 | 1 |
| 2012 | 1 | 1 | 2 |
| 2017 | 3 | 3 | 6 |
| 2018 | 3 | 1 | 4 |
| 2019 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Antidiuretic Hormone Receptor Antagonists" by people in Profiles.
-
Tolvaptan for Volume Management in Heart Failure. Pharmacotherapy. 2019 04; 39(4):473-485.
-
A Practical Guide for Treatment of Rapidly Progressive ADPKD with Tolvaptan. J Am Soc Nephrol. 2018 10; 29(10):2458-2470.
-
[Practical approach to patient therapy affected by Autosomal Dominant Autosomic Polycystic Kidney Disease]. G Ital Nefrol. 2018 Jul; 35(4).
-
Sudden Death After Hospitalization for Heart Failure With Reduced Ejection Fraction (from the EVEREST Trial). Am J Cardiol. 2018 07 15; 122(2):255-260.
-
Utilization and budget impact of tolvaptan in the inpatient setting among patients with heart failure and hyponatremia. Curr Med Res Opin. 2018 03; 34(3):559-566.
-
The vasopressin system: new insights for patients with kidney diseases: Epidemiological evidence and therapeutic perspectives. J Intern Med. 2017 10; 282(4):310-321.
-
Current Management of Hyponatremia in Acute Heart Failure: A Report From the Hyponatremia Registry for Patients With Euvolemic and Hypervolemic Hyponatremia (HN Registry). J Am Heart Assoc. 2017 Aug 03; 6(8).
-
Magnetic resonance T2 mapping and diffusion-weighted imaging for early detection of cystogenesis and response to therapy in a mouse model of polycystic kidney disease. Kidney Int. 2017 12; 92(6):1544-1554.
-
Antagonism of vasopressin V2 receptor improves albuminuria at the early stage of diabetic nephropathy in a mouse model of type 2 diabetes. J Diabetes Complications. 2017 Jun; 31(6):929-932.
-
Acute Heart Failure: Searching for a New Evident Truth. J Am Coll Cardiol. 2017 03 21; 69(11):1420-1423.